Susana Otero‐Romero

Defining high, medium and low impact prognostic factors for developing multiple sclerosis

Mar Tintoré, Àlex Rovira, Jordi Río et al. · Brain · 2015 · 520 citations

Medicine, Biostatistics, Neurology +15

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 386 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis

Carmen Tur, Pere Carbonell‐Mirabent, Álvaro Cobo‐Calvo et al. · JAMA Neurology · 2022 · 275 citations · Full text

Life Sciences, Neurology, Clinical Neuroscience +15

Retinal microvascular abnormalities in patients after COVID-19 depending on disease severity

Miguel Ángel Zapata, Sandra Banderas García, Adrián Sánchez-Moltalvá et al. · British Journal of Ophthalmology · 2020 · 101 citations · Full text

Medicine, Infectious Diseases, Ophthalmology +14

Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates

María Sepúlveda, Marta Aldea, Domingo Escudero et al. · Multiple Sclerosis Journal · 2017 · 100 citations · Full text

Medicine, Neurology, Disease Surveillance +14